SPRO 250117 5.00P (SPRO250117P5000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

SPRO250117P5000

Watchlist

0.00
0.000.00%

15min DelayClose Jan 10 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Spero Therapeutics Faces SEC Probe and Leadership Changes
TipRanksJan 10 07:31 ET
Spero Therapeutics Has Appointed Esther Rajavelu As Interim President And CEO, Stepping In For Sath Shukla, Who Has Agreed To A Voluntary Paid Administrative Leave For An Interim Period, The Board Has Also Appointed Director Frank Thomas As Chairman...
BenzingaJan 10 07:14 ET
Express News | Spero Therapeutics Inc - Sath Shukla on Voluntary Paid Administrative Leave for Interim Period
ReutersJan 10 07:03 ET
Express News | Spero Therapeutics Inc - Cash Runway Guidance Remains Into Mid-2026
ReutersJan 10 07:02 ET
Express News | Spero Therapeutics Inc - Frank Thomas Appointed Chairman of the Board
ReutersJan 10 07:00 ET
Express News | Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
ReutersJan 10 07:00 ET

Comments

Jaguar8

Oct 29, 2024 15:06

NEWS

$Spero Therapeutics (SPRO.US)$
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
Spero Therapeutics announced that its Phase 2a study of SPR720 for Nontuberculous Mycobacterial Pulmonary Disease failed to meet its primary endpoint. The interim analysis showed antimicrobial activity but insufficient separation from placebo, with safety concerns including three cases of reversible grade 3 hepatotoxicity. The company is suspending the SPR720 program and...

Jaguar8

Oct 16, 2024 15:06

NEWS

$Spero Therapeutics (SPRO.US)$
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
Spero Therapeutics announced a poster presentation at IDWeek 2024 showcasing in vitro data on SPR719, the active moiety of SPR720, for treating nontuberculous mycobacterium pulmonary disease (NTM-PD). The study, conducted with Microbiologics, revealed:
1. SPR719's low propensity for resistance d...

Jaguar8

Oct 2, 2024 15:31

NEWS

$Spero Therapeutics (SPRO.US)$
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
Spero Therapeutics (Nasdaq: SPRO) has published data from its Phase 1 clinical trial assessing the intrapulmonary pharmacokinetics of SPR719, the active moiety of SPR720, in Antimicrobial Agents and Chemotherapy. The study, involving 33 healthy subjects, showed significant lung uptake and enhanced concentrations of SPR719 in epithelial lining fl...

Tonyco

Sep 30, 2024 13:39

$Metagenomi Technologies, LLC (MGX.US)$ $Lantronix (LTRX.US)$
$Fate Therapeutics (FATE.US)$
$Navitas Semiconductor (NVTS.US)$
Opened up some positions on these today.
Increased $Rivian Automotive (RIVN.US)$ , $X4 Pharmaceuticals (XFOR.US)$
Took profit on $FTC Solar (FTCI.US)$ , $GigaCloud Technology (GCT.US)$ and $Aurora Innovation (AUR.US)$
I'll be back in GCT and AUR for sure.
Still looking at $Spero Therapeutics (SPRO.US)$ and $Acacia Research (ACTG.US)$ too.
Exciting day for dips!

Tonyco

Sep 21, 2024 23:12

$Spero Therapeutics (SPRO.US)$
Gonna be looking for under 1.3 to hop on. However, 9 days until their P2 trial concludes. If momentum builds, it may push it really high before then plummet after. Or, as I am hoping, it sinks until the news drops and gets a temp boost.
Right now, it looks likely to drop due to the MACD death cross.. we shall see